Off-target effects of PLX5622 revealed: mixing microglial function in anesthesia and addiction withdrawal

Kelei Cao, Cheng Wang, Liyao Qiu, Zexi Wang, Yuqing Zhao, Ying Yuan, Weiying Wu, Jing Xue, Linghui Zeng, Zhiying Wu, Huan Ma, Tingjun Hou, Cunqi Ye, Zhihua GaobioRxiv 2025 · DOI

TL;DR

This study reveals that the widely used microglial depletion agent, PLX5622, has significant off-target effects on hepatic metabolism, independent of microglial depletion. These metabolic changes confound interpretations of PLX5622's role in anesthesia and addiction withdrawal, highlighting the need for more specific CSF1R inhibitors.

What Problem Does This Paper Address?

Microglia, the brain's resident immune cells, are increasingly recognized for their crucial roles in various neurological functions and disorders. To study these roles, researchers often use pharmacological agents to deplete microglia. PLX5622, a potent inhibitor of the colony-stimulating factor 1 receptor (CSF1R), is a popular choice for this purpose, with studies suggesting it promotes faster emergence from anesthesia and can influence addiction-related behaviors. However, there's a growing concern that such broad-acting inhibitors might have unintended consequences beyond microglial depletion, potentially affecting other cell types or biological processes. This paper addresses the critical question of whether the observed effects of PLX5622 are solely due to microglial depletion or if other mechanisms are at play, which could lead to misinterpretations of microglial function.

Methods

The researchers employed a multi-faceted approach:

  • Pharmacological and Genetic Microglial Depletion: They used PLX5622 (a CSF1R inhibitor) for pharmacological depletion and diphtheria toxin (DT) in conjunction with a Cre-lox system (iDTR mice) for genetic depletion of microglia.
  • Anesthesia Assays: They tested the effects of PLX5622 on both injectable (pentobarbital, ketamine) and inhalational (isoflurane, sevoflurane) anesthesia, measuring induction and recovery times.
  • EEG/EMG Recordings: Continuous electroencephalography (EEG) and electromyography (EMG) were used to assess sleep-wake states and brain activity during anesthesia.
  • Metabolic Assays: They measured the concentrations of anesthetics (pentobarbital) and other drugs (efavirenz, ethanol, nicotine) in liver, plasma, and brain tissues over time to assess drug metabolism.
  • Gene Expression Analysis: RT-qPCR and RNA sequencing were used to examine the expression of genes related to drug metabolism, particularly cytochrome P450 (CYP) enzymes, in the liver.
  • Behavioral Tests: Standard behavioral paradigms like the open field test, light-dark box test, and elevated plus maze were used to assess anxiety-like behaviors in nicotine withdrawal models.
  • Adenosine Measurement: Fiber photometry with a genetically encoded adenosine sensor (GRABAdo) was used to measure extracellular adenosine levels in the prefrontal cortex during anesthesia.
  • Mass Spectrometry: LC-MS/MS and GC were used for precise quantification of drug metabolites.

Datasets

Not explicitly detailed as training or evaluation datasets in the context of machine learning. The study generated experimental data from mice, which are described in the Methods section.

Key Insights and Ideas

  • PLX5622 is a Metabolic Reprogrammer: The most striking finding is that PLX5622 significantly induces hepatic metabolic enzymes, particularly CYP2B10, leading to enhanced biotransformation of various xenobiotics (drugs) and endobiotics (endogenous metabolites).
  • Anesthesia Effects are Not Solely Microglial: While microglial depletion can influence anesthesia, the accelerated anesthetic emergence observed with PLX5622 is largely driven by its effect on liver metabolism, not just microglial action. This explains why PLX5622 is more potent than genetic microglial ablation in some contexts.
  • Addiction Phenotypes are Confounded: Similarly, the attenuation of nicotine withdrawal anxiety by PLX5622 is likely due to enhanced nicotine metabolism, rather than a direct effect on microglia's role in addiction.
  • Specificity Matters: The study underscores the critical need for highly specific CSF1R inhibitors that do not induce these broad metabolic changes, to accurately study microglial function.

Key Results

  • PLX5622 treatment did not affect inhalational anesthesia or overall vigilance states but significantly accelerated emergence from injectable anesthetics.
  • PLX5622 treatment robustly induced the expression of hepatic metabolic enzymes, including CYP2B10 (over 7000-fold induction), CYP2C37, and CYP3A11.
  • PLX5622 treatment enhanced the metabolism of pentobarbital, efavirenz, ethanol, and nicotine.
  • Genetic microglial depletion (using DT) did not produce the same metabolic changes or anesthetic effects as PLX5622.
  • Blocking CYP2B10 activity with clopidogrel partially restored anesthetic duration after PLX5622 treatment.
  • PLX5622 treatment reduced anxiety-like behaviors in nicotine withdrawal, but this effect was replicated by enhanced nicotine metabolism, not by genetic microglial depletion.

Limitations and Future Work

  • Off-target Effects: The primary limitation is the significant off-target effects of PLX5622 on hepatic metabolism, which confound the interpretation of microglial function.
  • Specificity of Inhibitors: The authors emphasize the need to design more specific CSF1R inhibitors that avoid these metabolic side effects.
  • Further Investigation of Mechanisms: While the study identifies CYP2B10 as a key player, further research could explore the precise molecular pathways through which PLX5622 induces these hepatic changes.
  • Translational Implications: The findings have implications for drug development, particularly for therapies targeting neurodegenerative diseases or psychiatric disorders where microglia and drug metabolism are relevant.

Summary updated

Abstract

Summary Microglia have gained increasing attention as important regulators in the brain. Acute microglial depletion using the colony-stimulating factor 1 receptor (CSF1R) inhibitor, PLX5622, has become a popular approach to uncover microglial function. PLX5622 treatment has been recently shown to significantly promote anesthetic emergence. In characterizing underlying mechanisms, we found that PLX5622 treatment did not change the global neuronal activity during anesthesia, but robustly enhanced anesthetic metabolism. Moreover, PLX5622 dramatically induced the expression of hepatic enzymes that extensively modify xenobiotic and endobiotic metabolism. Blocking increased enzymatic activity significantly reduced the arousal-promoting effects of PLX5622 in anesthesia, irrespective of microglial elimination. In addition, we demonstrate that enhanced drug metabolism also contributed to PLX5622-induced attenuation in nicotine-withdrawal anxiety. By revealing previously unrecognized effects of PLX5622, our findings raise caution in interpreting data generated from PLX5622 treatment and bring forward the need for designing more specific CSF1R inhibitors.
BibTeX
@misc{cao2025off,
  author = {Kelei Cao and Cheng Wang and Liyao Qiu and Zexi Wang and Yuqing Zhao and Ying Yuan and Weiying Wu and Jing Xue and Linghui Zeng and Zhiying Wu and Huan Ma and Tingjun Hou and Cunqi Ye and Zhihua Gao},
  title = {{Off-target effects of PLX5622 revealed: mixing microglial function in anesthesia and addiction withdrawal}},
  year = {2025},
  doi = {10.1101/2025.07.18.665493},
  howpublished = {bioRxiv},
}

Loading related content...

Figure